Nectar Lifescience
Nectar Lifescience Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Nectar Lifescience Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
Nectar Lifescience Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Nectar Lifescience Ltd, switchable between annual and quarterly views, consolidated or standalone.
Nectar Lifescience Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹227.29 Cr and reported EPS of ₹-8.06.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 1,901 | 2,783 | 2,367 | 1,544 | 1,669 | 1,525 | 1,686 | 1,673 | — |
| Other Income | 6 | 6 | 4 | 3 | 11 | 42 | 13 | 2 | 9 |
| Total Income | 1,907 | 2,789 | 2,371 | 1,547 | 1,680 | 1,567 | 1,699 | 1,675 | 9 |
| Cost of Goods Sold (COGS) | 1,367 | 2,218 | 1,859 | 1,157 | 1,223 | 1,159 | 1,202 | 1,368 | — |
| Gross Profit | 534 | 565 | 508 | 387 | 446 | 365 | 483 | 305 | — |
| +Operating Expenses | 297 | 301 | 288 | 277 | 287 | 311 | 330 | 332 | 61 |
| EBITDA | 237 | 264 | 220 | 110 | 159 | 54 | 153 | -26 | — |
| +Non-Operating Expenses | 180 | 211 | 187 | 147 | 136 | 139 | 148 | 137 | 36 |
| Profit Before Tax (PBT) | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -162 | -88 |
| +Tax Expense | 10 | 11 | 6 | -12 | 9 | -18 | 13 | -48 | -31 |
| Profit After Tax (PAT) | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -57 |
| Earnings Per Share (EPS) | 2.33 | 2.12 | 1.42 | -3.27 | 1.12 | -1.08 | 0.22 | -5.07 | -15.08 |
| Diluted Shares Outstanding (Nos.) | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 |
| +Additional Disclosures | 3,212 | 4,948 | 4,192 | 2,764 | 2,870 | 2,769 | 2,882 | 3,205 | -138 |
| Sales Growth % | — | 46.39 | -14.96 | -34.75 | 8.06 | -8.64 | 10.56 | -0.74 | — |
| YoY Sales Growth % | — | 46.39 | -14.96 | -34.75 | 8.06 | -8.64 | 10.56 | -0.74 | — |
| Material Cost % | 73 | 80 | 77 | 67 | 72 | 79 | 74 | 75 | — |
| Employee Cost % | 4 | 3 | 3 | 5 | 4 | 5 | 5 | 6 | — |
| Other Cost % | 12 | 8 | 9 | 13 | 13 | 15 | 15 | 14 | — |
| OPM % | 12 | 9 | 9 | 7 | 10 | 4 | 9 | -2 | — |
| Tax % | 17 | 19 | 15 | 14 | 27 | 43 | 73 | 30 | 35 |
| Profit Growth % | — | -8.94 | -33.22 | -330.47 | 134.19 | -196.55 | 120.65 | -2,376.07 | 49.55 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | — |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | -0.00 | — |
| Additional Fields | 172 | 201 | 159 | 50 | 102 | -5 | 92 | -89 | — |
Nectar Lifescience segment analysis: revenue and profit mix.
Disclosed business segments at Nectar Lifescience with their share of revenue and profit, switchable between consolidated and standalone reporting.
Nectar Lifescience discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Nectar Lifescience Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Nectar Lifescience Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Nectar Lifescience Ltd's investment case rests on 3 positive markers and 3 flagged concerns drawn from the latest reported filings.
What you're getting.
Despite recent losses, Nectar Lifesciences shows a history of profitability, with net profits reaching 11.66 in the March 2022 quarter. This suggests potential for future recovery and improved financial performance.
Promoter holding has remained relatively stable at around 55% historically, indicating a degree of confidence in the company's long-term prospects, even with recent fluctuations.
The company operates in the growing Pharmaceuticals sector within the Healthcare industry, offering potential for long-term growth and market share expansion, despite current challenges.
What can break it.
Nectar Lifesciences exhibits significant losses in recent quarters, with a negative net profit of -130 in the latest quarter and a substantial -22149% quarterly profit variation. This raises serious concerns about its financial health.
The company has a high debt-to-equity ratio of 0.61, indicating a considerable reliance on debt financing, which could increase financial risk and vulnerability to economic downturns.
The stock price has experienced significant volatility, falling from a high of 56.50 to a low of 13.00, indicating investor uncertainty and potential for further price declines. This volatility is a major risk for investors.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.11. Balance sheet risk re-prices growth multiples fast.
Nectar Lifescience Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Nectar Lifescience Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Nectar Lifescience Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Nectar Lifescience Ltd — derived from the live tape, not yesterday's close.
Nectar Lifescience Ltd last traded at ₹13.56 with an intraday range of ₹13.5–₹14.25 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹13.56| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 15.54 | +1.98 | +14.60% |
| R3 | 14.79 | +1.23 | +9.07% |
| R2 | 14.52 | +0.96 | +7.08% |
| R1 | 14.04 | +0.48 | +3.54% |
| PIVOT | 13.77 | 0.21 | 1.55% |
| CURRENT | 13.56 | — | — |
| S1 | 11.79 | -1.77 | -13.05% |
| S2 | 12.54 | -1.02 | -7.52% |
| S3 | 13.02 | -0.54 | -3.98% |
| S4 | 13.29 | -0.27 | -1.99% |
NECLIFE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ~
Trading Below opening range, showing Bearishness
Nectar Lifescience Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Nectar Lifescience Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Nectar Lifescience Ltd stood at 70.1% of traded volume, against a 20-day average of 63.7%.
Nectar Lifescience announcements: results, concalls, ratings, M&A.
Filings Nectar Lifescience sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Nectar Lifescience files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 96 documents below.
Copy of Newspaper Publication
Nectar Lifesciences Limited has informed the Exchange about Copy of Newspaper Publication
Outcome of Board Meeting
Nectar Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
General Updates
Nectar Lifesciences Limited has informed the Exchange about Update on Slump Sale
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Disclosure under SEBI Takeover Regulations
Sanjiv Goyal self and Karta of Sanjiv (HUF), Raman Goyal has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities…
Nectar Lifescience insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Nectar Lifescience as reported to SEBI — buying and selling signals from the people who know the business best.
Nectar Lifescience insider activity below tracks 1 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| RAMAN GOYAL | Insider | 19 Dec 2024 | buy | +4.00 L | ₹1.77 Cr | ₹44.37 |
Nectar Lifescience dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Nectar Lifescience has declared, sequenced by announce and record date.
Nectar Lifescience corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Nectar Lifescience Ltd: business, sector, key facts.
What Nectar Lifescience Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Nectar Lifescience Ltd operates in the Pharmaceuticals industry under the Health Care sector, listed as NSE: NECLIFE, BSE: 532649.
Nectar Lifesciences Limited, operating under the name NECLIFE, is a pharmaceutical company based in Chandigarh, India, with both domestic and international operations. Their core business revolves around the manufacturing and sale of pharmaceutical products, focusing heavily on the Cephalosporin class of antibiotics.
A significant portion of NECLIFE's business involves the production of Active Pharmaceutical Ingredients (APIs) and intermediates. These APIs form the building blocks of many finished medications and include a wide range of cephalosporins such as cefixime, cefuroxime axetil (in both amorphous and crystalline forms), cefotaxime sodium, ceftriaxone sodium, and several others. This demonstrates a specialization in the production of key components for a specific antibiotic family.
Beyond API manufacturing, NECLIFE offers contract manufacturing services for finished dosage forms. This means the company produces finished medications for other pharmaceutical companies, expanding their business model beyond just providing raw materials. The finished dosage forms they manufacture include tablets, capsules, dry powder oral suspensions, granules, and injectables, primarily focusing on cephalosporin-based medications based on their API production strengths.
In addition to their core pharmaceutical business, NECLIFE also produces and sells menthol and pearl capsules, indicating some diversification into other areas of the pharmaceutical and possibly supplement markets. This suggests a strategy to broaden their product portfolio and potentially target different market segments.
Established in 1995, NECLIFE has built a considerable presence in the pharmaceutical industry, demonstrating expertise in both API production and finished dosage form manufacturing. Their focus on cephalosporin antibiotics, coupled with contract manufacturing services, suggests a strategic approach to leverage their manufacturing capabilities and cater to the demands of a broad customer base.
Questions investors ask about Nectar Lifescience Ltd (NECLIFE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Nectar Lifescience Ltd (NECLIFE)?
The current share price of Nectar Lifescience Ltd (NECLIFE) is ₹13.56. Today, the stock has declined by ₹0.80 (5.57%), trading in a range of ₹13.5 to ₹14.25. The stock opened at ₹14.18 with a trading volume of 7,00,336 shares.
02Is Nectar Lifescience Ltd stock a good investment for long-term?
Nectar Lifescience Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹227.29 crores, P/E ratio of 0.00, ROE of -12.24%, and ROCE of -5.36%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Nectar Lifescience Ltd stock?
The 52-week high price of Nectar Lifescience Ltd (NECLIFE) is ₹24.89, while the 52-week low is ₹9.3. Currently trading at ₹13.56, the stock is 27.3% away from its 52-week low and 45.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Nectar Lifescience Ltd stock at the current price?
Whether to buy Nectar Lifescience Ltd stock at ₹13.56 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 0.49. Today's performance shows a loss of 5.57%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Nectar Lifescience Ltd and when is the next dividend?
Nectar Lifescience Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹13.56, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Nectar Lifescience Ltd?
Nectar Lifescience Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 0.49, ROE: -12.24%, ROCE: -5.36%, Dividend Yield: 0.00%, EPS: ₹-8.06, Book Value: ₹42.63, and Debt-to-Equity: 0.61. The company's market cap stands at ₹227.29 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Nectar Lifescience Ltd stock performing today in the market?
Nectar Lifescience Ltd stock opened at ₹14.18 and is currently trading at ₹13.56, showing a decline of ₹0.80 (5.57%). The intraday high is ₹14.25 and low is ₹13.5. The trading volume stands at 7,00,336 shares, indicating moderate market participation today.
08What is the P/E ratio of Nectar Lifescience Ltd and what does it indicate?
Nectar Lifescience Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-8.06, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Nectar Lifescience Ltd (NECLIFE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy